Please assess the completion status of the following clinical trial:

Trial Title: Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically and radiologically confirmed locally advanced pancreatic ductal adenocarcinoma and have not received prior therapy~* Disease is measurable by CT scan~* Age \>= to 18 years~* Life expectancy of 4 months or longer~* ANC \>/= 1,500mm/cm3~* Hemoglobin \>/= 9g/dl~* Platelet count \>/= 100,000/cm3~* Total bilirubin \</= 2 times control~* SGOT/SGPT \</= 2.5 times upper limit of normal~* Serum creatinine \< 2mg/dl~* No evidence of metastatic disease by laparoscopy~Exclusion Criteria:~* History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk for complications~* No secondary malignancies other than non-melanoma skin cancers or carcinoma in-situ of the cervix within past 5 years~* Patients with pre-existing peripheral neuropathy of grade 2 or greater~* Pregnant or lactating women~* Current, recent (within 4 weeks of study entry) or planned participation in an experimental drug study~* Blood pressure of \>150/100 mmHg~* Unstable angina~* New York Heart Association Grade II or greater congestive heart failure~* History of myocardial infarction or stroke within 6 months~* Clinically significant peripheral vascular disease~* Evidence of bleeding diathesis or coagulopathy~* Presence of central nervous system or brain metastases~* Major surgical procedure, open biopsy,m or significant traumatic injury within 28 days prior to day 0~* Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to day 0~* Urine protein creatinine ratio \> or = to 1.0 at screening~* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to day 0~* Serious, non-healing wound, ulcer, or bone fracture

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regimen Level 1 (Type: EXPERIMENTAL): Radiation/Oxaliplatin/5-FU
- Regimen Level 2 (Type: EXPERIMENTAL): Radiation/Oxaliplatin/Bevacizumab/5-FU

Based on this trial design, predict the completion outcome and termination type (if applicable).